Investor profile
Vectura Group plc is a public company listed on the London Stock Exchange. It is focused principally on the development of a range of inhaled pharmaceuticals for the treatment of respiratory and neurological diseases.
Vectura has a broad pipeline of products in clinical development and a portfolio of revenue-generating, marketed products. Its shares trade under the symbol VEC.
Vectura was founded in 1997 and acquired Innovata plc in January 2007. It has more than 230 employees, of whom 215 are engaged in research and development. Vectura is based in Chippenham, Wiltshire with additional facilities in Nottingham and Cambridge, UK.
Vectura's shares trade on the London Stock Exchange under the symbol VEC.
